{"id":"tp-53428","type":"article-newspaper","title":"Rani Therapeutics Posts $1.7 Million in Q3 Revenue, $0.04 GAAP Loss Per Share","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/53428","datePublished":"2026-11-11T00:19:25.000Z","dateModified":"2026-11-11T00:19:25.000Z","language":"en","abstract":"Cash, cash equivalents and marketable securities totaled $45.3 million on Sept. 30, 2026, down from $53.4 million on June 30. Rani expects those funds to cover operations through at least the end of 2027.","section":"Business","references":[]}